Potential conflict of interest: None provided.
Case-control analysis of survival outcomes in sinonasal acinic cell carcinoma
Article first published online: 5 MAR 2014
© 2014 ARS-AAOA, LLC
International Forum of Allergy & Rhinology
Volume 4, Issue 6, pages 507–511, June 2014
How to Cite
How to Cite this Article: Case-control analysis of survival outcomes in sinonasal acinic cell carcinoma. Int Forum Allergy Rhinol. 2014;4:507–511., , , .
Acinic cell carcinoma (AciCC) is a malignant-epithelial salivary gland malignancy most commonly arising in the parotid gland. Patients with AciCC generally have an excellent survival outcomes; however, patients with poorly differentiated tumors or metastatic disease have a significantly poorer prognosis.
- Issue published online: 3 JUN 2014
- Article first published online: 5 MAR 2014
- Manuscript Accepted: 30 DEC 2013
- Manuscript Revised: 13 DEC 2013
- Manuscript Received: 31 OCT 2013
Acinic cell carcinoma (AciCC) is an uncommon malignant-epithelial salivary gland cancer. In very rare cases, this tumor may arise from sinonasal subsites, with only 19 cases described in the English-language literature.
We performed a retrospective analysis of 18 cases of AciCC, obtained from searching the Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2009.
Patient demographics, including age, gender, and race, were similar to AciCC cases found in more common locations. However, all patients had low-grade tumors without regional or distant metastases. Comparing these patients to a stage, grade, and treatment–matched cohort of parotid AciCC, we found a lower 10-year overall survival (52.3%) with no significant difference in disease-specific survival (88.9%). Our meta-analysis of survival from cases in the literature estimated 10-year recurrence-free survival at 92.9%.
To our knowledge, this is the largest cohort of patients with AciCC reported in the English-language literature. Our results suggest that patients with sinonasal AciCC have excellent disease-specific survival, comparable to matched patients with AciCC in more common salivary gland subsites.